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Towards Long Wavelength Absorbing Photodynamic Therapy 
Photosensitizers via the Extension of a [Ru(bipy)3]2+ Core 
Johannes Karges,[a] Olivier Blacque,[b] Philippe Goldner,[c] Hui Chao,[d] and Gilles Gasser[a],* 
Abstract: Complementary to classical treatment methods used 
against cancer, photodynamic therapy (PDT) has received increased 
attention over the last years. PDT relies on the generation of reactive 
oxygen species (ROS) upon light irradiation to trigger cell death. As 
the wavelength employed during such treatments directly influences 
the light penetration depth and therefore the possibility to treat deep 
seated tumours or large tumours, research efforts have been made 
towards the development of photosensitizers (PS) with an absorption 
in the phototherapeutic window (600-900 nm). To tackle this drawback, 
we report herein the preparation and characterisation of new Ru(II)-
containing PDT PSs, that are based on a [Ru(bipy)3]2+ core (1; bipy: 
2,2'-bipyridine) and that are extended with methyl groups (2) or vinyl 
dimethylamino groups (3). As anticipated with our design, we found a 
red-shift of 65 nm of the maximum absorption of complex 3 in 
comparison to complex 1. In addition, we report on the in-depth 
photophysical properties as well as (photo-)cytotoxicity against 
cervical cancerous HeLa cells of the investigated compounds.  
Introduction 
Over the last decades, cancer has emerged to be one of the 
deadliest diseases worldwide.[1] Next to the classical treatments 
(e.g., chemotherapy, surgery and radiotherapy), the use of 
Photodynamic Therapy (PDT) has received increased attention 
as a complementary medical technique to these blockbusters. 
PDT is based on the combination of light, a photoactive 
compound called a Photosensitizer (PS) and oxygen. Ideally, the 
PS should be nontoxic in the absence of light and generate highly 
toxic species upon light irradiation. The mechanism of action of 
PDT is based on the generation of reactive oxygen species (ROS). 
More specifically, upon light irradiation, the PS is excited to a 
singlet state, which can be transformed into an excited triplet state 
by an intersystem crossing (ISC) process. From there, the PS is 
able to influence its biological environment by two pathways, 
namely Type I and Type II. During a Type I reaction, an electron 
or proton is transferred to/from the PS from/to its biological 
surrounding. This leads to the generation of radicals and ROS like 
superoxides or hydroxyl radicals. In a Type II reaction, the energy 
of the exited triplet state of the PS is transferred to molecular 
oxygen (3O2) to produce singlet oxygen (1O2). This highly 
energetic form of oxygen is highly reactive. Consequently, during 
both pathways, ROS or 1O2 react with its biological surrounding, 
generating cellular damages and therefore ultimately trigger cell 
death.[2] 
The most commonly used PS for PDT treatments is Photofrin 
(Figure 1), which is approved for the treatment of bladder cancer, 
early stage lung cancer, oesophageal cancer and early non-small 
cell lung cancer in various countries. To date, the majority of 
approved PSs are based on a tetrapyrrolic scaﬀold. Due to their 
relatively similar structures, the majority of these compounds 
have a tendency to share the same disadvantages, which are 1) 
poor water solubility; 2) tedious synthesis; 3) photobleaching 
effect and 4) slow clearance from the body causing 
photosensitivity. At this stage, it is important to mention that some 
compounds based on a tetrapyrrolic scaﬀold do not share these 
limitations.[2c, 3]   
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Figure 1. Structure of a) Photofrin and b) TLD-1433. [Ru(dmb)2(IP-TT)]2+ 
(dmb=4,4′-dimethyl-2,2′-bipyridine, IP-TT=2-(2′,2″:5″,2′ ′′-terthiophene)-
imidazol[4,5-f][1,10]phenanthroline). 
 
To tackle these drawbacks, new classes of PDT PSs are currently 
being developed. Among the different classes, Ru(II) polypyridyl 
complexes seem to be excellent candidates. The majority of these 
compounds have generally a high water solubility, long 
luminescence decay, high 1O2 production as well as a high 
chemical and photophysical stability.[4] Therefore, it is not 
surprising that the complex TLD-1433 (Figure 1, λex = 525 nm, 
εmax = 2000 M-1 cm-1, Φ ~ 0.99 in CH3CN) has just completed 
phase I clinical trial as a novel PDT PS for the treatment of bladder 
cancer.[4h, 5]  
To date, most studied Ru(II) polypyridyl complexes lack 
significant absorption in the phototherapeutic window (600-900 
nm).[6] It is well-established that the wavelength used during 
treatments directly correlates with the tissue penetration depth. 
Longer wavelengths are able to penetrate deeper in the tissue 
and are hence potentially able to treat deeper-seated tumours or 
larger tumours. Additionally, as longer wavelengths are less 
energetic, less photodamage caused by the light source has been 
associated with treatments at longer wavelengths. Based on this, 
PSs with an absorption at wavelengths in the phototherapeutic 
window are sought after.[7] 
With the aim to develop Ru(II) polypyridyl complexes with a red-
shift absorption in view of applications as PDT PSs, we have 
extended the parent complex [Ru(bipy)3]2+ (1) (bipy = 2,2′-
bipyridine) with methyl groups (2) and the conjugated system with 
vinyl dimethylamino groups (3) (Figure 2). Recent investigations 
have shown that the π-extension of the bipy core of the Ru(II) 
polypyridine complex caused a red shift of the absorption of the 
resulting complex.[8] In addition, previous systematic studies of 
differently substituted Ru(II) polypyridine complex have indicated 
that dialkylamino substituents strongly promote a desired red shift 
in absorption.[9] Combining these concepts, we report here 
compound 3, with an extended π-system and dimethylamine 
groups, which was indeed found to have a red-shifted absorption 
of 65 nm in comparison to complex 1 and an absorption in the 
phototherapeutic window as well as highly increased extinction 
coefficients. Importantly, we could show the ability of this 
compound to produce 1O2 at longer wavelengths as well as to 
cause phototoxicity at this wavelength in cancerous cells while 
having no observed dark toxicity.   
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Figure 2. Chemical structures of the investigated compounds in this study. The 
complexes were isolated as PF6 salts. 
 
Results and Discussion 
Synthesis and Characterisation 
The complexes synthesised in this work are shown in Figure 2. 
Compound 1 was obtained from a commercial source whereas 2 
was synthesised as previously reported by complexation of 
RuCl2dmso4 with 4,4´-dimethyl-2,2´-bipyridine.[10] To the best of 
our knowledge, the synthesis the complex 3 has not been yet 
reported. The ligand (E,E’)-4,4’-bis(N,N-dimethylaminovinyl)-2,2’-
bipyridine present in complex 3 was synthesised as previously 
reported.[11] However, complexation attempts of this ligand using 
similar conditions to complex 2 (e.g. in EtOH or DMF as well as 
addition of AgBF4 to remove the Cl ligands by precipitation of 
AgCl) were unsuccessful. Based on these findings, the synthetic 
procedure was changed (Scheme 1). As the first step, the 
complexation of RuCl2dmso4 with 4,4´-dimethyl-2,2´-bipyridine 
was performed. In a second step, an enamination reaction with 
tert-butoxy bis(dimethylamino)methane (Bredereck reagent) was 
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accomplished to obtain the desired compound 3. The signals in 
the NMR for 3 were correlated to their protons/carbons in the 
structure (numbering of the complex can be found in Figure S1) 
via 2D-NMR (Figures S4 and S5). The identity of complex 3 was 
confirmed by 1H- and 13C-NMR, ESI-HRMS (Figure S2, S3, S6) 
and the purity of all compounds verified by elemental analysis. 
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Scheme 1. Synthesis of complexes 2 and 3. a) 4,4´-dimethyl-2,2´-bipyridine, 
DMF, reflux, 12 h, nitrogen atmosphere, 92%; b) tert-butoxy 
bis(dimethylamino)methane, DMF, 140°C, 40 h, nitrogen atmosphere, 85%. 
 
X-ray crystallography  
The crystal structures of 4,4’-bis(N,N-dimethylaminovinyl)-2,2’-
bipyridine and 2 have been determined by single crystal X-ray 
diffraction studies. Crystal data, structure refinement parameters 
and molecular structures are presented in Table S1 as well as 
Figures 3 and S7.  The crystal structure of 4,4’-bis(N,N-
dimethylaminovinyl)-2,2’-bipyridine presented in the manuscript is 
a new monoclinic polymorph (a) of the previous structure (b) 
reported by Viau et al. in 2003.[12] The asymmetric unit in a 
contains one and a half molecules: one of the independent 
molecules lies on a center of inversion located in the middle of the 
central C – C bond while the second one occupies a general 
position. In both polymorphs the bipyridine derivative exhibits a 
classical transoid arrangement due to the repulsion of the nitrogen 
lone pairs and a E configuration of the enamine double bonds. 
Polymorphs a and b significantly differ from each other in the 
relative orientation of the C=C double bonds of the enamine 
moieties with the central rings. Indeed, in a they adopt a s-trans 
conformation with respect to C3-C4, C12-C13 and C20-C21 
(Figure S7) while in b a s-cis conformation is observed (see 
Figure S8). In our crystals the molecules are linked by C—H⋯N 
and C—H⋯π interactions. In the structure of the trisbipyridyl 
ruthenium(II) complex 2 the central Ru atom is expectedly 
coordinated to the six nitrogen atoms of the three substituted 
bipyridines in a distorted octahedral geometry. The complex 
cations crystallized with PF6- counter-ions and solvent molecules 
of diethyl ether in a ration 1/2/1. It is interesting to note that the 
crystal structure of 2 is isostructural with the previously reported 
crystal structure of the iron complex [Fe(4,4′-dimethyl-2,2′-
dipyridyl)3][PF6]2 (Figure S9).[13] In the crystal, ions and solvent 
molecules are linked together through C—H⋯F and C—H⋯O 
interactions. Despite the numerous aromatic rings of complex 2 
no π…π or C-H…π interactions are observed. 
 
Figure 3. Molecular structure of compound 2. The thermal ellipsoids are drawn 
at the 30 % probability level and all H atoms and the solvent molecule of diethyl 
ether are omitted for clarity.  
 
Photophysical properties 
The photophysical properties of the complexes were then 
evaluated to assess their potential as PDT PSs. To investigate 
this, we have measured the absorption of complexes 1-3 in 
CH3CN (Figure 4, Table 1). Typically, Ru(II) polypyridyl 
complexes have, as the lowest energy absorption band, a spin-
allowed metal-to-ligand charge transfer (MLCT) transition, which 
occurs for the prototype complex [Ru(bpy)3]2+ 1 at 450 nm. The 
band at 285 nm was assigned to spin-allowed ligand-centered 
(LC) transition and the shoulders around 350 nm to metal-
centered (MC) transitions.[6f] The comparison between complexes 
1 and 2 shows only small differences indicating that the additional 
methyl groups in 2 do not significantly influence the absorption 
properties. On the contrary, the absorption of complex 3 was 
highly modified with a strong increase of the extinction coefficient 
as well as a strong red-shift of 65 nm of the maximum of the MLCT 
transition caused by the extension of the π-system as well as the 
insertion of dimethylamine groups at the terminal end. Importantly, 
the absorption tail of the compound is in the desired 
phototherapeutic window (600-900 nm). For further investigation 
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of the excited state, the emission properties of the complexes 
were investigated upon excitation of the compounds in CH3CN at 
355 nm. The emission signal was measurable between 550-850 
nm (Figure S10) with a maximum at 622 nm for complex 2 and 
621 nm for complex 3. Comparison to the standard compound 1 
(Φem = 0.059) shows that complex 2 has an increased emission 
(Φem = 0.083) whereas complex 3 is only weakly emitting and 
could only be detected at the detection limit of our used setup. 
These results fit with those of a recent study which compared 
different 4,4´-π-conjugated[2,2´]-bipyridines and which found that 
(E,E’)-4,4’-bis(N,N’-dimethylaminovinyl)-2,2’-bipyridine itself 
already had a low fluorescence quantum yield of 0.015 in 
dichloromethane.[14] As an additional characterisation of the 
excited state, the luminescence lifetimes in degassed and air 
saturated CH3CN upon excitation at 355 nm were determined 
(Figure S11-S13). The measured lifetimes (Table 1) were found 
to be in the same range as for other investigated Ru(II) 
poylpyridine complexes.[9] Importantly, the lifetimes of the excited 
state is strongly decreasing in the presence of air. 
 
Table 1. Spectroscopic properties of the investigated complexes 1-3 in CH3CN 
at room temperature. λem  = emission maximum, Φem = luminescence quantum 
yield, τ = lifetime. 
 UV/Vis λ / nm 
 (ε / M-1 cm-1 * 10-3) 
λem / 
nm 
Φem  τ / ns 
    air degassed 
1 285 (80.8), 450 
(14.6) 
610 0.059 130 925 
2 285 (91.8), 325 
(13.3), 460 (16.6) 
622 0.083 109 1024 
3 295 (86.2), 385 
(149.7), 515 (56.4) 
621 <0.001 76 410 
 
 
Figure 4. Absorption spectra of complexes 1-3 in CH3CN.  
 
Singlet oxygen generation 
As discussed in the photophysical evaluation section, the lifetimes 
of the excited state of the investigated compounds are drastically 
decreasing in the presence of air indicating that the triplet state of 
the compound (3PS) is able to interact with molecular oxygen 
(3O2). As the active species for most applied PSs in PDT, the 
production of singlet oxygen (1O2) is responsible for most PDT 
effects. To investigate the ability of our compounds to generate 
1O2, we used two different methods, namely 1) direct by 
measurement of the phosphorescence of 1O2 or 2) indirect by 
measurement of the change in absorbance of a reporter 
molecule.[15] The results presented in Table 2 show that 
compounds 1 and 2 are generating 1O2 decently whereas 3 
generates 1O2 only poorly.  
 
Table 2. Singlet oxygen quantum yields in CH3CN and aqueous solution. 
Average of three independent measurements, ±10%. 
 direct 
450 nm 
CH3CN 
direct 
450 nm 
D2O 
indirect 
450 nm 
CH3CN 
indirect 
450 nm 
PBS 
indirect 
540 nm 
CH3CN 
Indirect 
540 nm 
PBS 
1 54% 21% 57% 20% n.d. a) n.d. a) 
2 66% 25% 64% 27% n.d. a) n.d. a) 
3 n.d. n.d. 21% 3% 18% 2% 
n.d. = not detectable. 
n.d. a) = not detectable due to missing absorbance at this wavelength. 
 
(Photo-)stability  
An important property of a molecule, which is envisioned to be 
used as a PDT PS, is its (photo-)stability. To investigate this, we 
have assessed the stability in organic solvents of our complexes 
as it was shown in previous works that this could already be 
problematic.[16] For this purpose, the compounds were incubated 
in CH3CN and, in time intervals (0, 1, 4, 8, 12, 24, 48 h), their 
UV/Vis spectra measured. During the incubation in CH3CN, no 
change in the spectra for all compounds (Figure S14-S16) could 
be detected indicating their stability in this solvent. As a second 
experiment, the stability in an aqueous PBS solution was 
investigated. Also, here, no decomposition was observed (Figure 
S17-S19), proving the stability of these compounds. Finally, as a 
third experiment, the complexes were incubated in human plasma 
and the stability of the complexes identified by an HPLC analysis. 
As an internal standard, caffeine was used, which has already 
been shown to be suitable for these experiments.[17] After 48 h 
incubation, the compounds were extracted from the plasma and 
the HPLC chromatogram before and after the incubation 
compared. The analysis showed that no decomposition for the 
compounds 1 and 2 (Figure S20-S21) occurred. On the contrary, 
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complex 3 was clearly transformed to a mixture of different kinds 
of unidentified products (Figure S22), clearly proving its 
decomposition. After investigation of the stability of the 
compounds in a biological environment, we have tested their 
stability upon irradiation in an air saturated CH3CN solution while 
monitoring their UV/Vis spectra in constant time intervals. The 
stability was compared to the PS Protoporphyrin IX (PpIX), which 
is well known to be photodegradating. The comparison between 
the spectra (Figure S23-S26) shows only a small decrease in 
absorption for 1 and 2 indicating only a small photobleaching 
effect.  On the contrary, the bands of 3 strongly decrease and shift, 
proving its decomposition upon light exposure. Consequently, the 
modification caused by the irradiation was investigated by NMR 
spectroscopy. For this purpose, a solution of 3 in CD3CN was 
irradiated at 450 nm (30 min, 36.0 J/cm2) and the change in the 
1H-NMR spectrum monitored. The compound was transformed in 
an unidentified mixture of different compounds (see Figure S27).  
 
Cellular Uptake 
A crucial parameter for the bioactivity of a molecule is its cellular 
uptake. To investigate this, compounds 1-3 were incubated for 4 
h in the dark in human cervical carcinoma (HeLa) cells. The 
amount of the metal Ru inside the cells was then determined 
using inductively coupled plasma mass spectrometry (ICP-MS). 
The results (Figure 5) show that complex 3 has a much higher 
uptake than 1 or 2.  
 
 
Figure 5. Comparison of the cellular uptake of complexes 1-3 after 4 h 
incubation in HeLa cells.   
 
 
Cytotoxicity and Phototoxicity 
After having assessed the chemical and photophysical properties 
of compounds 1-3, their influence on cell viability in the dark and 
upon light irradiation was investigated. For this purpose, the 
compounds were incubated in non-cancerous retinal pigment 
epithelium (RPE-1) and HeLa cells in the dark as well as upon 
light irradiation at 480 nm (10 min, 3.1 J/cm2) and 540 nm (40 min, 
9.5 J/cm2). The obtained IC50 values were further compared with 
the chemotherapeutic drug cisplatin and the PS Protoporphyrin IX 
(PpIX) (Table 3). For all investigated complexes, no toxicity in the 
dark could be observed (IC50 > 200 μM), which is a desired 
characteristic for a potential PDT PS. Disappointingly, the 
exposure to light had only a small effect on the cell viability for the 
three compounds. While no toxicity was observed for compounds 
1 and 2, compound 3 showed some phototoxicity. Of note, these 
findings are in agreement with a study of the [Ru(bipy)3]2+ complex 
which showed no dark and phototoxic effect in the high 
micromolar range.[18] To evaluate the ability of a compound to act 
as a PS, the phototoxic index (PI) is calculated as the ratio 
between the IC50 values in the dark and upon light exposure. For 
compound 3, a PI value of 1.3 at 480 nm and 1.4 at 540 nm for 
HeLa cells and 1.3 at 480 nm and 1.2 at 540 nm for RPE-1 cells 
was determined. These results demonstrate that 3 is able to have 
a slight phototoxic effect upon exposure to higher wavelength 
which is a desired characteristic for a PS. However, the obtained 
PI values are quite low in comparison to established PSs like PpIX. 
The results can be rationalised by the rather poor generation of 
singlet oxygen of this complex. One has also to highlight that the 
instability of this compound in human plasma and upon irradiation 
is extremely problematic and could also explain these poor 
biological results. Overall, the biological results obtained in this 
section are fitting with the ICP-MS experiments carried out which 
showed a much better cellular accumulation of complex 3 
compared to complexes 1 and 2. 
 
Table 3. IC50 values in the dark and upon irradiation at 480 (10 min, 3.1 J/cm2) 
and 540 nm (40 min, 9.5 J/cm2) for complexes 1-3 in comparison to cisplatin 
and Protoporphyrin IX (PpIX) on non-cancerous retinal pigment epithelium 
(RPE-1) and human cervical carcinoma (HeLa) cells. Average of three 
independent measurements. n.d. = not determinable. 
 HeLa RPE-1 
 Da
rk 
480 
nm 
PI 540 
nm 
PI Da
rk 
480 
nm 
PI 540 
nm 
PI 
1 >2
00 
>20
0 
n.
d. 
>20
0 
n.
d. 
>2
00 
>20
0 
n.
d. 
>20
0 
n.
d. 
2 >2
00 
>20
0 
n.
d. 
>20
0 
n.
d. 
>2
00 
>20
0 
n.
d. 
>20
0 
n.
d. 
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3 >2
00 
152
.4 ± 
3.8 
1.
3 
146
.3 ± 
4.2 
1.
4 
>2
00 
158
.5 ± 
8.1 
1.
3 
161
.7 ± 
6.2 
1.
2 
PpIX >1
00 
2.5 
± 
0.1 
>4
0 
2.1 
± 
0.3 
>4
8 
>1
00 
3.8 
± 
0.1 
>2
6 
3.1 
± 
0.1 
>3
2 
Cispl
atin 
10.
5 ± 
0.8 
- - - - 29.
3 ± 
1.4 
- - - - 
n.d. = not determinable. 
Conclusions 
In this study, we aimed to shift the absorption wavelength of the 
MLCT transition of Ru(II) polypyridyl complexes towards the red 
region to enable the use of longer wavelengths during PDT 
treatments. This would allow for deeper tissue penetration and 
therefore the possibility to treat deep-seated tumours and larger 
tumours. For this purpose, the [Ru(bipy)3]2+ complex was 
extended with methyl groups (2) and the conjugated system 
extended with vinyl dimethylamino groups (3). The compounds 
were characterized in-depth including by 2D-NMR techniques and 
single crystal X-ray crystallography. Whereas the photophysical 
properties of 2 were found to be in the same range as for the 
standard complex 1, compound 3 showed a highly increased 
absorption as shown by the very high extinction coefficients as 
well as a strong red shift of 65 nm. Further analysis of the 
photophysical properties revealed that this compound was weakly 
emissive and has short excited state lifetimes. We assume that 
these properties are limiting the necessary energy transfer from 
the excited state 3PS to molecular oxygen (3O2) to ultimately 
produce singlet oxygen (1O2). This probably explains the poor 
singlet oxygen quantum yield determined in this study for complex 
3. Investigation of the stability of the compounds revealed that 
complexes 1 and 2 are stable in CH3CN, PBS and human plasma 
whereas 3 decomposes in human plasma as well as upon light 
irradiation over time. Biological evaluation on the cancerous cell 
line HeLa and the non-cancerous cell line RPE-1 revealed no dark 
toxicity for any of the investigated complexes in this study. While 
no toxicity upon light exposure for compounds 1 and 2 could be 
observed, complex 3 showed some slight phototoxicity in the high 
micromolar range against cervical cancerous HeLa cells and 
importantly no measurable dark cytotoxicity. Despite 
unfavourable photophysical properties, 3 showed a stronger 
cytotoxic effect than the two other complexes 1 and 2. 
Quantification of the cellular uptake of the complexes by ICP-MS 
experiments rationalized this observation with complex 3 being 
much better taken up by HeLa cells than compounds 1 and 2. 
Overall this study demonstrates how the extension of the 
[Ru(bipy)3]2+ core through methyl groups (2) or vinyl 
dimethylamino groups (3) effects their photophysical properties 
including their absorption. We are currently investigating other 
options to synthesise Ru(II) polypyridyl complexes with a stronger 
luminescence, higher production of 1O2 as well as stability in a 
biological environment as well as upon light exposure. 
 Experimental Section 
Materials 
All chemicals were obtained from commercial sources and used without 
further purification. Tris(2,2′-bipyridine)ruthenium(II) hexafluorophosphate 
[Ru(bipy)3][PF6]2 (1) was bought from Sigma Aldrich. The Ru(II) precursor 
RuCl2dmso4 was synthesised as previously reported.[19] The ligand (E,E’)-
4,4’-bis(N,N-dimethylaminovinyl)-2,2’-bipyridine present in complex 3 was 
synthesised as previously reported.[11] 
 
Instrumentation and methods 
1H and 13C NMR spectra were recorded on a Bruker 500 MHz NMR 
spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) 
referenced to tetramethylsilane (δ 0.00) ppm using the residual proton 
solvent peaks as internal standards. Coupling constants (J) are reported 
in Hertz (Hz) and the multiplicity is abbreviated as follows: s (singlet), d 
(doublet), dd (doublet of doublet). ESI-MS experiments were carried out 
using a LTQ-Orbitrap XL from Thermo Scientific and operated in positive 
ionization mode, with a spray voltage at 3.6 kV. No Sheath and auxiliary 
gas was used. Applied voltages were 40 and 100 V for the ion transfer 
capillary and the tube lens, respectively. The ion transfer capillary was held 
at 275°C. Detection was achieved in the Orbitrap with a resolution set to 
100,000 (at m/z 400) and a m/z range between 150-2000 in profile mode. 
Spectrum was analyzed using the acquisition software XCalibur 2.1 
(Thermo Fisher Scientific).  The automatic gain control (AGC) allowed 
accumulation of up to 2*105 ions for FTMS scans, Maximum injection time 
was set to 300 ms and 1 µscan was acquired. 10 µL was injected using a 
Thermo Finnigan Surveyor HPLC system (Thermo Fisher Scientific) with 
a continuous infusion of methanol at 100 µL.min-1. Elemental 
microanalyses were performed on a Thermo Flash 2000 elemental 
analyser. For analytic HPLC the following system has been used: 2 x 
Agilent G1361 1260 Prep Pump system with Agilent G7115A 1260 DAD 
WR Detector equipped with an Agilent Pursuit XRs 5C18 (100Å, C18 5 μm 
250 x 4.6 mm) Column. The solvents (HPLC grade) were millipore water 
(0.1% TFA, solvent A) and acetonitrile (0.1% TFA, solvent B). Inductively 
coupled plasma mass spectrometry (ICP-MS) experiments were carried 
out on an iCAP RQ ICP-MS instrument (Thermo Fisher). 
 
Synthesis 
[Ru(4,4′-Dimethyl-2,2′-dipyridyl)3][PF6]2 (2)  
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[Ru(4,4′-Dimethyl-2,2′-dipyridyl)3][PF6]2 (2) was synthesized as previously 
published[8] using RuCl2dmso4. Experimental data fits with the literature. 
Purity of the sample was assessed by HPLC and elemental analysis. 
Elemental analysis calcd for C36H36F12N6P2Ru (%): C 45.82, H 3.85, N 
8.91; found: C 45.71, H 3.69, N 8.83. 
[Ru((E,E’)-4,4’-Bis(N,N-dimethylaminovinyl)-2,2’-bipyridine)3][PF6]2 
(3) 
[Ru(4,4′-Dimethyl-2,2′-dipyridyl)3][PF6]2 (2) (188 mg, 0.20 mmol, 
1.0 equiv.) was dissolved in dry DMF (12 mL) under nitrogen atmosphere 
and tert-Butoxy bis(dimethylamino)methane (0.9 mL, 4.36 mmol, 
21.8 equiv.) was added slowly. The mixture was heated at 140 °C for 40 
h. The solution was then cooled down and a sat. aqueous solution of 
NH4PF6 was added. The crude product, which precipitated as a PF6 salt 
was collected by filtration and washed with H2O and Et2O. The product 
was isolated via fractionated precipitation from CH3CN by adding dropwise 
Et2O. 215 mg of 3 (0.17 mmol, 85 %) were yielded as a dark red solid. 1H-
NMR (CD3CN, 500 MHz): 7.98 (d, 4J = 2.0 Hz, 6H, H3), 7.45 (d, 3J = 13.4 
Hz, 6H, H8), 7.24 (d, 3J = 6.2 Hz, 6H, H6), 6.90 (dd, 3,4J = 6.2, 2.0 Hz, 6H, 
H5), 5.09 (d, 3J = 13.4 Hz, 6H, H7), 2.94 (s, 36H, H10). 13C-NMR (CD3CN, 
125 MHz): δ = 157.8 (C2), 150.2 (C4), 150.0 (C6), 147.0 (C8), 120.2 (C5), 
116.7 (C3), 93.0 (C7), 40.9 (C10). ESI-HRMS (pos. detection mode): calcd 
for C54H66N12Ru m/z [M]2+ 492.2283; found: 492.2284. Elemental analysis 
calcd for C54H66F12N12P2Ru (%): C 50.90, H 5.22, N 13.19; found: C 50.64, 
H 4.96, N 12.90. 
X-ray crystallography  
X-ray single-crystal data were collected at low temperatures, 160(1) K for 
4,4’-bis(N,N-dimethylaminovinyl)-2,2’-bipyridine and at 183(1) K for 
compound 2, with an Oxford liquid-nitrogen Cryostream cooler on a Rigaku 
OD XtaLAB Synergy Dualflex (Pilatus 200K detector) diffractometer. A 
single wavelength X-ray source from a micro-focus sealed X-ray tube were 
used with the Cu Kα radiation (λ = 1.54184 Å)[20] for both analyses. The 
selected single crystals were mounted using polybutene oil on a flexible 
loop fixed on a goniometer head and transferred to the diffractometer. Pre-
experiments, data collections, data reductions and analytical absorption 
corrections[21] were performed with the program suite CrysAlisPro.[22] 
Using Olex2,[23] the structures were solved with the SHELXT[24] small 
molecule structure solution program and refined with the SHELXL2018/3 
program package[25] by full-matrix least-squares minimization on F2. 
Molecular graphics were created using Mercury 4.0.[26] The crystal data 
collections and structure refinement parameters are summarized in Table 
S1. CCDC 1914096 (for 2) and CCDC 1914097 (for 4,4’-bis(N,N-
dimethylaminovinyl)-2,2’-bipyridine) contain the supplementary 
crystallographic data for these compounds, and can be obtained free of 
charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Spectroscopic measurements 
The absorption of the samples has been measured with a SpectraMax M2 
Spectrometer (Molecular Devices). The emission was measured by 
irradiation of the sample in fluorescence quartz cuvettes (width 1 cm) using 
a NT342B Nd-YAG pumped optical parametric oscillator (Ekspla) at 355 
nm. Luminescence was focused and collected at right angle to the 
excitation pathway and directed to an Acton SP-2300i monochromator 
(Princeton Instruments). As a detector a PI-Max 4 CCD camera (Princeton 
Instruments) has been used. 
 
Luminescence quantum yield measurements 
For the determination of the luminescence quantum yield, the samples 
were prepared in a not degassed CH3CN solution with an absorbance of 
0.1 at 355 nm. This solution was irradiated in fluorescence quartz cuvettes 
(width 1 cm) using a NT342B Nd-YAG pumped optical parametric oscillator 
(Ekspla) at 355 nm. The emission signal was focused and collected at right 
angle to the excitation pathway and directed to an Acton SP-2300i 
monochromator (Princeton Instruments). As a detector a XPI-Max 4 CCD 
camera (Princeton Instruments) has been used. The luminescence 
quantum yields were determined by comparison with the reference 
[Ru(bipy)3]Cl2 in CH3CN (Φem=5.9%)[27] applying the following formula: 
Φem, sample = Φem, ref * (Fref / Fsample) * (Isample / Iref) * (nsample / nref)2 
F = 1 – 10-A 
Φem = luminescence quantum yield, F = fraction of light absorbed, I = 
integrated emission intensities, n = refractive index, A = absorbance of the 
sample at irradiation wavelength. 
 
Lifetime measurements 
For the determination of the lifetimes, the samples were prepared in an air 
saturated and in a degassed CH3CN solution with an absorbance of 0.2 at 
355 nm. This solution was irradiated in fluorescence quartz cuvettes (width 
1 cm) using a NT342B Nd-YAG pumped optical parametric oscillator 
(Ekspla) at 355 nm. The emission signal was focused and collected at right 
angle to the excitation pathway and directed to an Acton SP-2300i 
monochromator (Princeton Instruments). As a detector a R928 
photomultiplier tube (Hamamatsu) has been used. 
 
Singlet oxygen measurements  
- Direct evaluation 
The samples were prepared in an air saturated CH3CN or D2O solution 
with an absorbance of 0.2 at 450 nm. This solution was irradiated in 
fluorescence quartz cuvettes (width 1 cm) using a mounted M450LP1 LED 
(Thorlabs) whose irradiation, centered at 450 nm, has been focused with 
aspheric condenser lenses. The intensity of the irradiation has been varied 
using a T-Cube LED Driver (Thorlabs) and measured with an optical power 
and energy meter. The emission signal was focused and collected at right 
angle to the excitation pathway and directed to an Acton SP-2300i 
monochromator (Princeton Instruments). A longpass glass filter was 
placed in front of the monochromator entrance slit to cut off light at 
wavelengths shorter than 850 nm. As a detector an EO-817L IR-sensitive 
liquid nitrogen cooled germanium diode detector (North Coast Scientific 
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Corp.) has been used. The singlet oxygen luminesce at 1270 nm was 
measured by recording spectra from 1100 to 1400 nm. For the data 
analysis, the singlet oxygen luminescence peaks at different irradiation 
intensities were integrated. The resulting areas were plotted against the 
percentage of the irradiation intensity and the slope of the linear regression 
calculated. The absorbance of the sample was corrected with an 
absorbance correction factor. As reference for the measurement rose 
bengal (Φ = 76 %)[28] was used and the singlet oxygen quantum yields 
were calculated using the following formula: 
Φsample = Φreference * (Ssample / Sreference) * (Ireference / Isample) 
I = I0 * (1 – 10-A) 
Φ = singlet oxygen quantum yield, S = slope of the linear regression of the 
plot of the areas of the singlet oxygen luminescence peaks against the 
irradiation intensity, I = absorbance correction factor, I0 = light intensity of 
the irradiation source, A = absorbance of the sample at irradiation 
wavelength. 
- Indirect evaluation 
For the measurement in CH3CN: The samples were prepared in an air-
saturated CH3CN solution containing the complex with an absorbance of 
0.2 at the irradiation wavelength, N,N-dimethyl-4-nitrosoaniline aniline 
(RNO, 24 µM) and imidazole (12 mM). For the measurement in PBS buffer: 
The samples were prepared in an air-saturated PBS solution containing 
the complex with an absorbance of 0.1 at the irradiation wavelength, N,N-
dimethyl-4-nitrosoaniline aniline (RNO, 20 µM) and histidine (10 mM). The 
samples were irradiated on 96 well plates with an Atlas Photonics LUMOS 
BIO irradiator for different times. The absorbance of the samples was 
measured during these time intervals with a SpectraMax M2 Microplate 
Reader (Molecular Devices). The difference in absorbance (A0-A) at 420 
nm for the CH3CN solution or at 440 nm a PBS buffer solution was 
calculated and plotted against the irradiation times. From the plot the slope 
of the linear regression was calculated as well as the absorbance 
correction factor determined. The singlet oxygen quantum yields were 
calculated using the same formulas as used for the direct evaluation.  
 
Stability in CH3CN and PBS 
The stability of the compound in CH3CN and PBS was determined by 
UV/Vis spectroscopy. The compound was dissolved and stored at room 
temperature in the dark. The absorption spectrum from 250-700 nm was 
recorded with a SpectraMax M2 Microplate Reader (Molecular Devices) 
after each time interval (0, 1, 4, 8, 12, 24, 48 h) and compared. 
 
Stability in human plasma 
The stability of the complexes was evaluated with caffeine as an internal 
standard, which has already shown to be suitable for these experiments.[17] 
The pooled human plasma was obtained from Biowest and caffeine from 
TCI Chemicals. Stock Solutions of the compounds (40 μM) and caffeine 
(20 μM) were prepared in DMSO. One aliquot of the solutions was added 
to 975 μL of human plasma to a total volume of 1000 μL. Final 
concentrations of the compounds of 0.5 μM  n-and caffeine of 0.25 μM 
were achieved. The resulting solution was incubated for 48 h at 37 °C with 
continuous gentle shaking (ca. 300 rpm). The reaction was stopped after 
the incubation time by addition of 2 mL of methanol. The mixture was 
centrifuged for 45 min at 650 g at 4 °C. The methanolic solution was filtered 
through a 0.2 μm membrane filter. The solvent was evaporated under 
reduced pressure and the residue was dissolved in 1:1 (v/v) CH3CN/ H2O 
0.1% TFA solution. The solution was filtered through a 0.2 μm membrane 
filter and analysed using an HPLC System. Based on the big differences 
in lipophilicity, two different HPLC methods have been used. The solvents 
(HPLC grade) were millipore water (0.1% TFA, solvent A) and acetonitrile 
(solvent B). Method M1: 0-3 minutes: isocratic 95% A (5% B); 3- 17 
minutes: linear gradient from 95% A (5% B) to 0% A (100% B); 17-23 
minutes: isocratic 0% A (100% B). Method M2: 0-3 minutes: isocratic 80% 
A (20% B); 3-17 minutes: linear gradient from 80% A (20% B) to 0% A 
(100% B); 17-23 minutes: isocratic 0% A (100% B). The flow rate was 1 
mL/min and the chromatogram was detected at 250 nm. 
 
Photostability  
The samples were prepared in an air saturated CH3CN solution. To 
measure the photostability, the samples were irradiated at 450 nm in 96 
well plates with an Atlas Photonics LUMOS BIO irradiator during time 
intervals from 0-10 min. The absorbance spectrum from 350-700 nm was 
recorded with a SpectraMax M2 Microplate Reader (Molecular Devices) 
after each time interval and compared.  
 
Cell culture 
Human cervical carcinoma (HeLa) cells were cultured using DMEM media 
and retinal pigment epithelium (RPE-1) cells using DMEM/F-12 with 
addition of 10% FBS and 1% penstrep. The cells were cultivated and 
maintained at 37 °C in a cell culture incubator at 37 °C with 5% CO2 
atmosphere. Before an experiment, the cells were passaged three times. 
 
Cellular uptake  
The cellular uptake of the complex was investigated by the determination 
of the Ru content inside the cells. The complex with a final concentration 
of 25 μM (1% DMSO, v%) was incubated for 4 h at 37 °C in the dark on a 
cell culture dish with a density of ca. 6 . 106 cells in 10 mL of media. After 
this time, the media was removed and the cells were washed with cell 
media. The cells were trypsinised, harvested, centrifuged and 
resuspended. The number of cells on each dish was accurately counted. 
Each sample was the digested using a 60% HNO3 solution overnight. Each 
sample was diluted to solution of 2% HNO3 in water. The Ru content was 
determined using an ICP-MS apparatus and comparing the results with the 
Ru references. The Ru content was then associated with the number of 
cells. 
 
(Photo-)cytotoxicity 
The cytotoxicity of the compounds was accessed by measuring the cell 
viability using a fluorometric resazurin assay. The cultivated cells were 
seeded in triplicates in 96 well plates with a density of 4000 cells per well 
in 100 μL of media. After 24 h the medium was removed and the cells were 
FULL PAPER    
 
 
 
 
 
treated with increasing concentrations of the compound diluted in cell 
media achieving a total volume of 200 μL. The cells were incubated with 
the compound for 4 h. After this time, the media was removed and replaced 
with 200 μL of fresh medium. For the phototoxicity studies, the cells were 
exposed to light with an Atlas Photonics LUMOS BIO irradiator. Each well 
was constantly illuminated with either a 480 nm or 540 nm irradiation. 
During this time, the temperature was maintained constantly at 37 °C. The 
cells were grown in the incubator for additional 44 h. For the determination 
of the dark cytotoxicity, the cells were not irradiated and after the medium 
exchange directly incubated for 44 h. After this time, the medium was 
replaced with fresh medium containing resazurin with a final concentration 
of 0.2 mg/mL. After 4 h incubation, the amount of the fluorescent product 
resorufin was determined upon excitation at 540 nm and measurement its 
emission at 590 nm using a SpectraMax M2 Microplate Reader (Molecular 
Devices). The obtained data was analysed with the GraphPad Prism 
software. 
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The preparation and characterisation 
of new Ru(II)-containing photodynamic 
therapy, that are based on a 
[Ru(bipy)3]2+ core (bipy: 2,2'-bipyridine) 
and that are extended with methyl 
groups or vinyl dimethylamino groups 
is described. Their in-depth 
photophysical properties as well as 
(photo-)cytotoxicity against cervical 
cancerous HeLa cells is also reported. 
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